Table 1 Clinical characteristics of the patients.

From: MRI-based 3D-printed surgical guides for breast cancer patients who received neoadjuvant chemotherapy

Number

Age

Multiplicity

Size I

Size II

HG

ER

PR

HER2

SISH amplified

KI-67 (%)

Chemotherapy

1

44

No

2.2

0.6

2

0

0

3

 

80–90

AC + T + H

2

61

No

3.1

0.3

3

6

0

2

Yes

70–80

AC + T

3

42

No

2.4

1

2

2

0

1

 

90–100

AC + T

4

49

No

2.5

0.8

2

8

5

0

 

10–20

AC + T + H

5

48

Yes

7.1

6.8

2

8

8

2

No

20–30

AC + T

  1. Size I: Tumor size determined by using magnetic resonance imaging (MRI) before neoadjuvant chemotherapy.
  2. Size II: Tumor size determined by using MRI after neoadjuvant chemotherapy.
  3. HG: Histological grade.
  4. ER: Estrogen receptor status.
  5. PR: Progesterone receptor status.
  6. HER2: Human epidermal growth factor receptor 2 status.
  7. SHSI: Silver in situ hybridization.
  8. AC: Adriamycin and cyclophosphamide.
  9. T: Docetaxel.
  10. H: Herceptin (trastuzumab).